FDAnews Drug Daily Bulletin

Anthera Buys Liprotamase from Lilly, Plans Phase III Trial

July 17, 2014
A A
Eli Lilly has sold liprotamase to Anthera Pharmaceuticals, three years after the FDA halted development of the investigational pancreatic enzyme replacement therapy (PERT) through a complete response letter that followed an advisory committee recommendation against approval of the compound. The price was not disclosed.
GEN